TrialHub Clinches DPHARM Idol Disrupt 2025 by Prioritizing Patient-Centric Clinical Trials
In a groundbreaking achievement, TrialHub has been crowned the winner of the prestigious DPHARM Idol Disrupt 2025 award during the 15th annual DPHARM: Disruptive Innovations to Modernize Clinical Research event. This recognition highlights the company's commitment to bringing research closer to patients by revolutionizing the design and execution of clinical trials. The DPHARM conference, renowned for showcasing innovations in the clinical research landscape, saw TrialHub stand out amongst its competitors, including Dandelion Health, Grove AI, and IgniteData.
TrialHub, led by its CEO and Co-founder Maya Zlatanova, aims to address the critical issue of patient recruitment in clinical trials, which often faces significant delays. With a staggering 80% of clinical trials experiencing recruitment hurdles, the need for a shift in how trials are designed has never been more apparent. Zlatanova passionately articulated this sentiment during her presentation, emphasizing that the industry must adapt protocols to fit patients rather than expecting patients to conform to rigid trial designs. "It's time we start adapting protocols to patients, not the other way around," she stated.
The company employs an innovative approach by automating standard-of-care research across more than 70 countries, allowing for the design of patient-aligned protocols. This strategy not only optimizes site selection but also hastens the recruitment process while minimizing costly amendments. Zlatanova's insight into mapping the patient journey—from diagnosis to treatment—provides a comprehensive understanding of the What, When, Where, Who, and How of patient experiences. This method ensures that trials are not just theoretically sound but practically viable in real-world settings.
As part of the competition, TrialHub presented its strategies to a panel of 13 eminent judges, including leading RD executives, patient advocates, and life science investors. The judges underscored the significance of creating adaptable patient journeys and country-specific pathways in trial operations, which help in designing well-structured trials that inherently meet the needs of patients.
"TrialHub is bringing research closer to patients by helping to design trials that match the patient, and not the other way around," remarked Siân Ratcliffe, PhD, Senior Vice President and Head of Quantitative Sciences Development Operations at Biogen, who served as a judge at the event.
Despite stiff competition from notable contenders like Elliott Green of Dandelion Health and Richard Yeatman of IgniteData, TrialHub's patient-centric vision propelled it to victory. The judges' panel included distinguished figures such as Mohammed Ali of Astellas, Esther Dyson, and clinical innovation leaders from organizations such as Genentech and Novartis. Their extensive expertise in clinical operations and patient advocacy provided valuable insights into the evolving demands of clinical research.
The DPHARM Idol Disrupt 2025 event not only serves to highlight innovative companies but also fosters a collaborative environment where ideas for modernizing clinical trials can be exchanged. This year's iteration was moderated by Sean Lynch, who oversees innovative trial operations at Novartis. Furthermore, Valerie Bowling, Executive Director of the Conference Forum, along with her team, ensured the smooth execution of discussions surrounding crucial advancements in clinical research.
TrialHub's success at DPHARM Idol Disrupt reflects a broader move within the industry towards integrating patient feedback and experiences into the design of clinical protocols. As the landscape of clinical trials continues to evolve, the emphasis on making research more accessible and relevant to patients will only grow stronger. By harnessing technology and innovative practices, TrialHub is poised to lead the charge in shaping a more patient-centric future for clinical research.
For more information and continuous updates on clinical trial innovations, visit theconferenceforum.org. In doing so, anyone interested in transforming the clinical research landscape is encouraged to follow the developments led by innovative teams like TrialHub, who are dedicated to enriching patient experiences in research settings.
TrialHub, led by its CEO and Co-founder Maya Zlatanova, aims to address the critical issue of patient recruitment in clinical trials, which often faces significant delays. With a staggering 80% of clinical trials experiencing recruitment hurdles, the need for a shift in how trials are designed has never been more apparent. Zlatanova passionately articulated this sentiment during her presentation, emphasizing that the industry must adapt protocols to fit patients rather than expecting patients to conform to rigid trial designs. "It's time we start adapting protocols to patients, not the other way around," she stated.
The company employs an innovative approach by automating standard-of-care research across more than 70 countries, allowing for the design of patient-aligned protocols. This strategy not only optimizes site selection but also hastens the recruitment process while minimizing costly amendments. Zlatanova's insight into mapping the patient journey—from diagnosis to treatment—provides a comprehensive understanding of the What, When, Where, Who, and How of patient experiences. This method ensures that trials are not just theoretically sound but practically viable in real-world settings.
As part of the competition, TrialHub presented its strategies to a panel of 13 eminent judges, including leading RD executives, patient advocates, and life science investors. The judges underscored the significance of creating adaptable patient journeys and country-specific pathways in trial operations, which help in designing well-structured trials that inherently meet the needs of patients.
"TrialHub is bringing research closer to patients by helping to design trials that match the patient, and not the other way around," remarked Siân Ratcliffe, PhD, Senior Vice President and Head of Quantitative Sciences Development Operations at Biogen, who served as a judge at the event.
Despite stiff competition from notable contenders like Elliott Green of Dandelion Health and Richard Yeatman of IgniteData, TrialHub's patient-centric vision propelled it to victory. The judges' panel included distinguished figures such as Mohammed Ali of Astellas, Esther Dyson, and clinical innovation leaders from organizations such as Genentech and Novartis. Their extensive expertise in clinical operations and patient advocacy provided valuable insights into the evolving demands of clinical research.
The DPHARM Idol Disrupt 2025 event not only serves to highlight innovative companies but also fosters a collaborative environment where ideas for modernizing clinical trials can be exchanged. This year's iteration was moderated by Sean Lynch, who oversees innovative trial operations at Novartis. Furthermore, Valerie Bowling, Executive Director of the Conference Forum, along with her team, ensured the smooth execution of discussions surrounding crucial advancements in clinical research.
TrialHub's success at DPHARM Idol Disrupt reflects a broader move within the industry towards integrating patient feedback and experiences into the design of clinical protocols. As the landscape of clinical trials continues to evolve, the emphasis on making research more accessible and relevant to patients will only grow stronger. By harnessing technology and innovative practices, TrialHub is poised to lead the charge in shaping a more patient-centric future for clinical research.
For more information and continuous updates on clinical trial innovations, visit theconferenceforum.org. In doing so, anyone interested in transforming the clinical research landscape is encouraged to follow the developments led by innovative teams like TrialHub, who are dedicated to enriching patient experiences in research settings.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.